Transforming medicine

Annual General Meeting Results and Statement

Acacia Pharma’s BARHEMSYS® Significantly Improves Post-operative Nausea & Vomiting (PONV) in Rescue Treatment of Ambulatory Patients

Notice of Annual General Meeting

Acacia Pharma Receives Complete Response Letter from FDA for BARHEMSYS®

Positive Phase 3 BARHEMSYS® Rescue Treatment Data to be Presented at the Annual Congress of Enhanced Recovery and Perioperative Medicine

Results for the year ended 31 December 2018

Editorial in Anesthesiology on Positive Data for BARHEMSYS™ PONV Rescue Treatment

Supportive Cardiac Safety Data for BARHEMSYS™

Positive Clinical Results for APD403 in CINV Published in Supportive Care in Cancer

New BARHEMSYS™ PDUFA date confirmed for 5 May 2019

Positive BARHEMSYS™ Rescue Treatment Data Published in Anesthesiology

Acacia Pharma Resubmits BARHEMSYS™ New Drug Application

Unaudited Results for the nine months to 30 September 2018

Further update on FDA regulatory review of BARHEMSYS™ 

Update on FDA regulatory review of BARHEMSYS™

Positive BARHEMSYS™ Phase 3 Treatment Data Published in Anesthesia & Analgesia

Interim Results for the First Half Year 2018

Operating Update for the First Half 2018

$30 Million Credit Facility with Hercules Technology Growth Capital Secured to Support Intended Commercialisation of BARHEMSYS™ in the US

US Commercial Operations for BARHEMSYS™ (formerly BAREMSIS®) Expanded Four Key Appointments

BARHEMSYS™ (formerly BAREMSIS®) Prevents Post-Operative Nausea & Vomiting In High-Risk Patients (published in Anesthesiology)

FDA Acceptance Of NDA Filing For BAREMSIS® For The Management Of PONV

Positive Results From 4th And Final Pivotal Phase 3 Trial Of BAREMSIS® For Rescue Treatment Of PONV

Positive Results From Pivotal Phase 3 Trial Of BAREMSIS® For The Treatment Of PONV

Initiation Of Second Pivotal Phase 3 Treatment Trial With BAREMSIS® In PONV